Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026)

Alnylam Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$176.0 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 11.6% year-over-year to -$176.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (up 191.89% YoY) and the FY2025 annual result came in at $75.1 million, down 17.59% from the prior year.
• Change in Accured Expenses was -$176.0 million for Q1 2026 at Alnylam Pharmaceuticals, down from -$174.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $223.5 million in Q3 2025 and bottomed at -$176.0 million in Q1 2026.
• A 5-year average of $15.5 million and a median of $68.1 million in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 167.37% in 2025, while the deepest fall reached 3142.24% in 2025.
• Alnylam Pharmaceuticals' Change in Accured Expenses stood at $102.6 million in 2022, then sank by 137.68% to -$38.7 million in 2023, then plunged by 60.62% to -$62.1 million in 2024, then slumped by 181.54% to -$174.9 million in 2025, then retreated by 0.67% to -$176.0 million in 2026.
• Business Quant data shows ALNY's Change in Accured Expenses at -$176.0 million in Q1 2026, -$174.9 million in Q4 2025, and $223.5 million in Q3 2025.